- Home
- PUBM vs ENLV Comparison
PUBM vs ENLV Comparison
Compare PUBM & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PUBM | ENLV |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.6M | 249.3M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PUBM | ENLV |
|---|---|---|
| Price | $8.13 | $1.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $18.44 | $13.00 |
| AVG Volume (30 Days) | ★ 813.8K | 206.6K |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,926,000.00 | N/A |
| Revenue This Year | $3.33 | N/A |
| Revenue Next Year | $8.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.15 | $0.66 |
| 52 Week High | $13.26 | $2.10 |
Technical Indicators
Market Signals| Indicator | PUBM | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 56.39 | 45.53 |
| Support Level | $7.97 | $1.00 |
| Resistance Level | $9.12 | $1.07 |
| Average True Range (ATR) | 0.46 | 0.07 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 63.56 | 11.36 |
Price Performance
Historical ComparisonAbout PUBM PubMatic Inc.
PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.